Lincoln Pharmaceuticals Limited

LINCOLN

INE405C01035

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 03:10:56 2024-05-16 EDT			5-day change	1st Jan Change
595.2 ^INR	-0.50%		+4.89%	-1.81%

03-30	Lincoln Pharmaceuticals Limited Announces Pirabhai Suthar Will Cease to Be an Independent Director	CI
02-22	Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director	CI

Lincoln Pharmaceuticals Limited Informs About Demise of Shri Ishwarlal Ambalal Patel Independent Director

December 05, 2022 at 05:03 am

Lincoln Pharmaceuticals Limited informed about demise of Shri Ishwarlal Ambalal Patel (DIN: 00217324), Independent Director of the Company, on December 04, 2022. Shri Ishwarlal Ambalal Patel's sudden and unexpected passing away will be an irreplaceable loss to the Company and all the directors and employees of the Company convey deep sympathy, sorrow and condolences to his family.

Latest news about Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited Announces Pirabhai Suthar Will Cease to Be an Independent Director	03-30	CI
Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director	02-22	CI
Lincoln Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Lincoln Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-02	CI
Lincoln Pharmaceuticals Limited Declares Dividend for the Financial Year 2022-23	23-09-30	CI
Lincoln Pharmaceuticals Limited Proposes Dividend for the Financial Year 2022-2023	23-09-06	CI
Lincoln Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Lincoln Pharmaceuticals Limited Recommends A Dividend for the Year Ended March 31, 2023	23-05-25	CI
Lincoln Pharmaceuticals Limited Approves the Resignation of Anand A. Patel from the Position of Whole Time Director as Well as Director of the Company	23-05-25	CI
Lincoln Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-25	CI
Lincoln Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-09	CI
Lincoln Pharmaceuticals Limited Informs About Demise of Shri Ishwarlal Ambalal Patel Independent Director	22-12-05	CI
Lincoln Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10	CI
Lincoln Pharmaceuticals Limited Appoints Trusha Shah as Company Secretary and Compliance Officer	22-11-10	CI
Lincoln Pharmaceuticals Limited Approves to Declare Dividend for the Financial Year 2021-22	22-09-30	CI
Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022	22-09-06	CI
Lincoln Pharmaceuticals Limited Approves Appointment of Anand A. Patel as an Additional and Whole Time Director	22-08-09	CI
Lincoln Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-09	CI
Lincoln Pharmaceuticals Limited Announces Resignation of Niren A. Desai as Company Secretary / Compliance Officer, with Effect from July 19, 2022	22-07-20	CI
Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2022	22-05-19	CI
Lincoln Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-10	CI
Lincoln Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-11	CI
Lincoln Pharmaceuticals Limited Approves Dividend for the Financial Year Ended on March 31, 2021	21-10-20	CI
Lincoln Pharmaceuticals : Gets Regulatory Approval to Launch Products in Australia	21-10-08	MT
Lincoln Pharmaceuticals : Buys Facility for Antimicrobial Drug Production	21-09-21	MT

Chart Lincoln Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Lincoln Pharmaceuticals Limited is engaged in the business of manufacturing and trading of pharmaceuticals products like medicines, injections and other related products. The Companyâs product categories include tablets, capsules, liquid injection, cream in tubes, eye/ear drops, dry power injection, liquid in bott, liquid injection and pharma products. It has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, vitamin-minerals and iron preparations, among others. The Company serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia and 26 States across India. The Company's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms) and Tinnex Capsule used to treat tinnitus.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LINCOLN PHARMACEUTICALS LIMITED	-1.81%	144M
NOVO NORDISK A/S	+31.37%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	211B
ROCHE HOLDING AG	-6.95%	203B
AMGEN INC.	+10.77%	171B
PFIZER, INC.	+0.10%	163B

Other Pharmaceuticals